Ablexis Appoints R. Scott Greer Chairman of the Board and Richard Hoffman Chief Business Officer
Published: Jun 22, 2010
SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, announced today the appointments of R. Scott Greer as chairman of the board of directors and Richard Hoffman as chief business officer. These important additions reunite three key leaders from the strategic, commercial and technical foundation of Abgenix, Inc., which was acquired by Amgen for $2.2 billion in 2006. Together, they will apply more than 60 years’ combined experience and know-how in the field to further enhance and execute Ablexis’ business strategy.